Drug Profile


Alternative Names: PK 26124; Rilutek; RP 54274

Latest Information Update: 09 Apr 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action Glutamate receptor antagonists; Glutamate-release-inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis
  • No development reported Anxiety disorders
  • Discontinued Parkinson's disease; Psychotic disorders

Most Recent Events

  • 09 Apr 2013 No development reported - Preclinical for Anxiety disorders in USA (PO)
  • 04 Apr 2013 Riluzole licensed to Covis Pharma in USA
  • 06 Aug 2012 Launched for Amyotrophic lateral sclerosis in Australia (PO) before Aug 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top